Acquisition of resistance to anti-cancer drugs is a significant obstacle to effective cancer treatment. Although several efforts have been made to overcome drug resistance in cancer cells, the detailed mechanisms have not been fully elucidated. Here, we investigated whether microRNAs (miRNAs) function as pivotal regulators in the acquisition of anti-cancer drug resistance to 5-fluorouracil (5-FU). A survey using a lentivirus library containing 572 precursor miRNAs revealed that five miRNAs promoted cell survival after 5-FU treatment in human hepatocellular carcinoma Hep3B cells. Among the five different clones, the clone expressing miR-200a-3p (Hep3B-miR-200a-3p) was further characterized as a 5-FU-resistant cell line. The cell viability and growth rate of Hep3B-miR-200a-3p cells were higher than those of control cells after 5-FU treatment. Ectopic expression of a miR-200a-3p mimic increased, while inhibition of miR-200a-3p downregulated, cell viability in response to 5-FU, doxorubicin, and CDDP (cisplatin). We also showed that dual-specificity phosphatase 6 (DUSP6) is a novel target of miR-200a-3p and regulates resistance to 5-FU. Ectopic expression of DUSP6 mitigated the pro-survival effects of miR-200a-3p. Taken together, these results lead us to propose that miR-200a-3p enhances anti-cancer drug resistance by decreasing DUSP6 expression.
INTRODUCTION
Multidrug resistance is a major factor leading to cancer treatment failure. It is a multifactorial phenomenon that includes the reduction of cell death, an increase in DNA repair, and alterations in drug metabolism. [1] [2] [3] [4] [5] Because acquisition of drug resistance and toxic side effects limit the clinical applications of anti-cancer drugs, several studies have attempted to define the molecular and biochemical mechanisms related to the resistant phenotypes of cancer cells. [6] [7] [8] [9] [10] However, the key determinants of drug resistance still remain largely unknown. 5-Fluorouracil (5-FU) is widely used to treat a range of cancers, including colorectal, liver, and breast cancers. 7, 11 5-FU is known to interfere with the synthesis of the pyrimidine thymidine, a nucleoside required for DNA replication, by inhibiting thymidylate synthase, thereby leading to cell cycle arrest or cell death in cancer cells. 7 However, the acquisition of 5-FU resistance is one of the biggest obstacles for cancer therapy, and factors or mechanisms governing resistance need to be defined to increase the efficacy of chemotherapy. microRNAs (miRNAs) are a conserved class of small non-coding RNAs that control gene expression by inducing mRNA degradation or by suppressing mRNA translation. 12 miRNAs execute essential regulatory roles in cancer progression as oncogenes or tumor suppressors by affecting cell growth, death, migration, and differentiation; thus, their differential expression is linked to cancer development. [13] [14] [15] [16] In addition, several studies have highlighted emerging roles of miRNAs in anti-cancer drug resistance. [5] [6] [7] [8] [9] Accumulating evidence suggests that the miR-200 family (miR-200a, -200b, -200c , -141 and -429) regulates the pathogenesis of several types of cancer: it plays crucial roles in cell proliferation, metastasis, epithelial-mesenchymal transition, and anti-cancer drug resistance. [17] [18] [19] [20] [21] [22] [23] [24] Here, we demonstrated that miR-200a-3p is a novel factor regulating anti-cancer drug resistance in response to 5-FU. Using a lentivirus library containing miRNA precursors, we identified miR-200a-3p as a regulatory miRNA promoting cell survival after 5-FU treatment and investigated the correlation between miR-200a-3p and 5-FU resistance in human hepatocellular carcinoma Hep3B cells. miR-200a-3p increased cell viability, while inhibition of miR-200a-3p sensitized Hep3B cells in response to 5-FU treatment. In silico analysis and a functional study further revealed that miR-200a-3p regulates the response to 5-FU in Hep3B cells by targeting dual-specific phosphatase 6 (DUSP6). Our study suggests that targeting the miR-200a-3p-DUSP6 axis could be a therapeutic strategy for overcoming chemoresistance in cancer therapy.
MATERIALS AND METHODS

Establishment of 5-fluorouracil-resistant clones
Human hepatocellular carcinoma Hep3B cells were transduced using a lentivirus library containing 572 precursor miRNAs (System Bioscience, Inc., Pala Alto, CA, USA) for 72 h (the multiplicity of infection was 10). To establish resistant cell lines, cells were re-plated in 100 mm dishes and incubated with medium containing 10 μM 5-FU. Two weeks later, each colony was established as 5-FUresistant Hep3B clones.
Identification of miRNAs in lentiviral clones
To identify microRNAs overexpressed in lentivirus-infected clones, genomic DNA from each clone was prepared using an AccuPrep Genomic DNA extraction Kit (Bioneer Corp., Korea) according to the manufacturer's instructions, and the miRNA sequences integrated into genomic DNA were amplified by polymerase chain reaction with the specific primer pairs listed in Table 1 . The amplicons containing miRNA sequences were isolated, and the sequences were determined using the sequencing primers pCDH-5.1-Fwd, 5′-GCCTGGAGA CGCCATCCACGCTG-3′ and pCDH-3.1-Rvs, 5′-GATGTGCGCT CTGCCCACTGAC-3′ (System Bioscience, Inc.).
Cell culture, cloning and transfection
Hep3B-CTRL, Hep3B-miR-200a and Hep3B cells were maintained with Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum and 1% antibiotics. Enhanced green fluorescent protein (EGFP) reporter plasmids were constructed by insertion of the DUSP6 mRNA 3 0 UTR region (2385-2573, 189 nt) into pEGFP-C1 (BD Bioscience, San Jose, CA, USA). A mutant reporter lacking the binding sites for miR-200a-3p was generated by site-directed mutagenesis using a KOD-PlusMutagenesis Kit (Toyobo, Japan). The GFP-DUSP6 plasmid was a kind gift from Prof TH Kim at Chosun University. 25 Transfection of plasmids or microRNA oligos was performed using Lipofectamine 2000 (Invitrogen).
MTT assay
Cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). In brief, cells were transfected with miR-200a-3p mimic, inhibitor or control miRNA and incubated with anti-cancer drugs for 72 h and then further incubated with 0.5 mg/ml of MTT for 3 h. Formazan crystals were solubilized with 100 μl of 40 mM acidic isopropanol, and the absorbance was measured at 570 nm using a Victor 3 microplate reader (Perkin Elmer, Finland).
RNA analysis and RT-qPCR
Total RNAs were isolated using TRIzol reagent (Invitrogen). For mRNA analysis, cDNAs were prepared via reverse transcription using random hexamers and reverse transcriptase (Toyobo, Osaka, Japan). cDNAs for miRNA detection were synthesized using a Mir-X miRNA First Strand Synthesis kit (Clontech, Mountain View, CA, USA). The abundance of transcripts was assessed by quantitative PCR (qPCR) analysis using SYBR Green PCR master mix (Kapa Biosystems, Wilmington, MA, USA) and gene-specific primer sets on a StepOne Plus instrument (Applied Biosystems, Foster City, CA, USA). GAPDH mRNA and U6 RNA were used as the internal controls for normalization. Primer sequences are listed in Table 1 .
Flow cytometric analysis
Cell cycle distribution was assessed using fluorescence-activated cellsorting (FACS) analysis by tracing propidium iodide-stained nuclei as previously described. 26 After 5-FU treatment, cells were incubated with propidium iodide (Sigma Aldrich, St Louis, MO, USA) and analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences).
Western blotting
Whole cell lysates were prepared using RIPA buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 0.1% SDS), separated by electrophoresis in SDS-containing polyacrylamide gels, and transferred onto PVDF membranes (EMD Millipore, Billerica, MA, USA). The membranes were incubated with primary antibodies against DUSP6 and EGFP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or β-actin (Abcam, Cambridge, MA, USA) and then further incubated with the appropriate secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology). Chemiluminescent signals were visualized using NEW Clarity ECL substrate (Bio-Rad, Hercules, CA, USA). For quantitative analysis, the density of the individual images was analyzed using ImageJ software (NIH, Bethesda, MD, USA).
Colony forming assay
After incubating cells with 5-FU or DMSO for 72 h, 1 × 10 3 cells per well were cultured for 2 weeks. Cells were fixed with 4% paraformaldehyde and stained with 0.05% crystal violet for 10 min at room temperature. After washing and drying the plates, the number of colonies was estimated by counting colonies from three random fields (35 mm 2 ) per sample.
RESULTS
Establishment of resistant Hep3B-Lenti-miR clones to 05-fluorouracil
To identify miRNAs involved in the acquisition of anti-cancer drug resistance, we transduced lentiviral particles containing 572 precursor miRNAs into human hepatocellular carcinoma and tumor necrosis factor receptor superfamily member 10b (TNFRSF10B) are putative targets of miR-200a-3p (Figure 5a ). Among these targets, we examined DUSP6 regulation by miR-200a-3p. To assess the roles of miR-200a-3p in DUSP6 regulation, we analyzed both mRNA and protein levels after 
DISCUSSION
Multidrug resistance is one of the major obstacles for chemotherapy. Understanding the mechanisms of both intrinsic and acquired resistance is important for providing specific targeted therapy and to gain novel insights into the regulation of cancer progression, as well as for the development of novel agents. 1, 32 Although several efforts have been made to overcome multidrug resistance, the mechanism of drug resistance still remains largely unknown. In this study, we investigated the underlying mechanisms of miRNAs in the acquisition of drug resistance. To identify miRNAs as active drivers that regulate the acquisition of 5-FU resistance, we 17, 19, 20, 23 It was previously reported that miR-200s have tumor suppressive effects on cell transformation, proliferation, migration, and invasion by downregulating various target mRNAs such as the E-cadherin repressors ZEB1/2 (SIP1), and in particular, miR-200b/c functions as a tumor suppressor in certain cell types. [19] [20] [21] 33 In addition, previous studies have shown that miR-200a is involved in breast cancer development by regulating specific target mRNAs, including YAP1, KEAP1, EPHA2 and SIRT1. 23, [34] [35] [36] [37] It was also reported that miR-200a regulates the expression of MAPK14, STAT5B, SIM2-s and β-catenin in ovarian, kidney and brain cancer. [38] [39] [40] Here, we demonstrated that miR-200a-3p promoted the acquisition of resistance to 5-FU by targeting DUSP6, thereby promoting cell survival after 5-FU treatment. Minimal evidence makes it difficult to determine the dominant function of the miR-200 family as enhancers or suppressors of cancer progression. It seems that the controversial roles of the miR-200 family may be due to its relative level and differential regulation in certain cell or cancer types. Further functional validation is needed to understand the roles of the miR-200 family in various types of cancer.
DUSP6/MKP-3 is a cytoplasmic, ERK-specific phosphatase that plays a crucial role in cancer development and progression by dephosphorylating ERK1/2. 41, 42 It has been reported that DUSP6 is upregulated in myeloma, melanoma, glioma, breast and pancreatic cancer, whereas it is downregulated in pancreatic ductal carcinoma, lung and ovarian cancer. [43] [44] [45] [46] [47] [48] [49] [50] [51] While DUSPs/MKPs have a crucial role in cancer progression, how they are differentially expressed in certain cell types or certain circumstances is not fully understood. It has been reported that expression of DUSPs/MKPs could be modulated by p53, FGF or β-catenin signaling 25, 52, 53 and that their activity is differentially regulated by post-translational modifications, such as phosphorylation or ubiquitination. 54, 55 In addition, several factors affecting DUSP expression at the RNA level have been identified. For example, the RNA-binding proteins HuR and NF90 are involved in the regulation of DUSP1 expression by stabilizing DUSP1 mRNA. 56 Additionally, miR-29b downregulated DUSP2 expression, and miR-145-/181a/125b were involved in a decrease in DUSP6 levels. [57] [58] [59] [60] In this study, we provided experimental evidence that miR-200a-3p is a novel regulator that reduces DUSP6 expression ( Figure 5 ).
Because DUSPs/MKPs play a role in both cancer progression and cancer resistance, 25 targeting DUSPs/MKPs could provide novel therapeutics. In this study, we demonstrated that a high level of miR-200a-3p is responsible for an increase in resistance to 5-FU (Figure 2) , and inhibition of miR-200a-3p decreased cell growth and viability after 5-FU treatment, thereby sensitizing Hep3B cells to anti-cancer drugs, including 5-FU, CDDP, and doxorubicin (Figures 3 and 4) . These results suggest that inhibition of miR-200a-3p has the potential to reduce chemoresistance in response to various anti-cancer drugs. The relative expression levels of miR-200a-3p among 5-FU-resistant cells or in patient groups with chemoresistance were not assessed in this study. Further analysis of the differential expression of miR-200a-3p in various types of resistant cells would be helpful in understanding the relationship between drug resistance and miR-200a-3p. Previous studies reported that miR-200a inhibited doxorubicin-induced cell death, 61 and a high level of miR-200a in hepatocellular carcinoma cells increased resistance to curcumin. 62 To assess whether 5-FU affects miR-200a-3p expression, we investigated the levels of miR-200a-3p and pre-miR-200a after 5-FU treatment in Hep3B cells. There were no significant changes in miR-200a-3p level until 72 h after 5-FU treatment (data not shown). Because the acquisition of drug resistance may not occur within a short period, another approach is needed to determine whether 5-FU directly regulates miR-200a-3p expression and whether the differential level of miR-200a-3p is a driving force leading to the acquisition of drug resistance. In addition, the clinical significance of miR-200a-3p in chemoresistance requires further investigation. In this study, we demonstrated that stable expression of miR-200a-3p promoted cell survival in response to anti-cancer drugs, and miRNA inhibition using anti-miR-200a-3p sensitized cells via DUSP6 regulation. These results indicate that miR-200a-3p plays an important role in promoting cell survival in response to 5-FU, and the miR-200a-3p-DUSP6 axis is involved in the acquisition of drug resistance. Our study provides novel insights into the function of miR-200a-3p, which enable the development of a prognostic marker or therapeutic strategy using antimiR-200a-3p to increase the efficacy of chemotherapy.
